SAN DIEGO, Oct. 2, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCQB:INNV) announced today the selection of an oral podium presentation of Zestra®, its clinically proven topical product to increase female sexual arousal and desire entitled, "Female Arousal and Orgasmic Complaints in a Diverse Cancer Population Treated with Zestra®: A Topical Applied Blend of Oils", at the World Meeting on Sexual Medicine, which will take place in Sao Paulo, Brazil, from October 8 to 12, 2014. The podium presentation will be given by Dr. Michael Krychman and is scheduled under The Arousal and Desire session on Thursday, October 9, 11:30 am - 12:30 pm. Innovus will also exhibit two posters. The moderated poster entitled "Treatment Paradigm for Women with Arousal and Orgasmic Complaints", under the Women's Sexual Medicine session is scheduled for presentation on Saturday, October 11, 14:00 - 15:30 hrs. The non-moderated poster presentation entitled "Female Arousal and Orgasmic Complaints in a Diverse Female Population with Multiple Medical Issues Treated with Zestra®" will be exhibited digitally for the duration of the meeting from October 8 to 12th, 2014.
Dr. Michael L. Krychman is the Executive Director of the Southern California Center for Sexual Health and Survivorship Medicine located in Newport Beach California, USA and he is a member of the Zestra® international Clinical Advisory Board.
The Company markets Zestra® in the US and Canada and recently announced multiple commercial partnerships to commercialize the product in the Middle East, North Africa and West Africa and with a new partner in Canada.
About Zestra® and FSI/AD
Zestra® is a patented blend of natural oils clinically-proven in double-blind, placebo-controlled, clinical trials in 276 women to increase in a statistically significant manner the arousal, desire and sexual satisfaction in FSI/AD women. Zestra® is the first NHP product to receive approval for the indication of FSDD and the Company filed for label expansion to FSI/AD in Canada. To date, no product has been approved in the Canada to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger.
About Innovus Pharmaceuticals, Inc.
Innovus Pharmaceuticals, Inc. (OTCQB:INNV), located in San Diego, California, is an emerging pharmaceuticals company that delivers safe, innovative and effective non-prescription over-the counter medicine and consumer care products to improve men and women's health and vitality. Our products are marketed in the United States and Canada via retailers and on the web. The Company also details its products to urologists, gynecologists and sex therapists either directly in the United States or through commercial partners ex-US. Its current product portfolio is comprised of Zestra® (for female arousal, desire and satisfaction), EjectDelay™ (for premature ejaculation), Sensum+™ (for reduced penile sensitivity) and Zestra Glide® (A high viscosity low molarity female water based lubricant). For more information, go to www.innovuspharma.com; www.ejectdelay.com; www.zestra.com; www.sensumplus.com
Innovus Pharma's Forward-Looking Safe Harbor Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products and to achieve its other development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.